Results 1 to 10 of about 5,144 (141)

Ixekizumab

Turkderm Turkish Archives of Dermatology and Venereology, 2022
Ixekizumab is a human immunoglobulin G4 monoclonal antibody targeting interleukin-17A. Clinical trials have reported that 82-84% of the patients using ixekizumab achieved a PASI90 response at week 12 and 85% at week 60.
İlgen Ertam Sağduyu
doaj   +8 more sources

Treatment Persistence of Interleukin-17 Inhibitors and Factors Associated with Persistence in Patients with Psoriasis Vulgaris in Japan: Retrospective Database Study [PDF]

Dermatology and Therapy
Introduction Psoriasis vulgaris (PsV) is a chronic, immune-mediated skin disorder that significantly impairs quality of life and often necessitates long-term systemic therapy, especially in moderate-to-severe cases.
Yayoi Tada, Hideaki Kagitani, Shuichi Kimura, Naoto Tsujimoto, Kiyotaka Mochizuki   +4 more
doaj   +2 more sources

Effectiveness and safety of switching biologics after secukinumab treatment failure in moderate-to-severe plaque psoriasis: a retrospective cohort study [PDF]

Frontiers in Medicine
BackgroundBiologic switching is common in clinical practice for patients with moderate-to-severe plaque psoriasis who fail secukinumab therapy. There is limited real-world evidence comparing different switching strategies, especially within-class vs ...
Zhongyu Zhang, Zhongyu Zhang, Zhongyu Zhang, Zhongyu Zhang, Bin Zhang, Bin Zhang, Bin Zhang, Bin Zhang, Yating Wen, Yating Wen, Yating Wen, Yating Wen, Qian Hu, Qian Hu, Qian Hu, Qian Hu, Wenjun Jiang, Wenjun Jiang, Wenjun Jiang, Wenjun Jiang, Jia Zhuo, Jia Zhuo, Jia Zhuo, Jia Zhuo, Guangying Luo, Guangying Luo, Guangying Luo, Guangying Luo, Yuyi Wang, Yuyi Wang, Yuyi Wang, Yuyi Wang   +31 more
doaj   +2 more sources

Does HLA-B27 Status Influence Ixekizumab Efficacy in Axial Spondyloarthritis? Results From the COAST-V, COAST-W, and COAST-X Trials [PDF]

Rheumatology and Therapy
Introduction The human leukocyte antigen (HLA)-B27 is associated with axial spondyloarthritis (axSpA) and is a predictor of response to tumor necrosis factor inhibitors. However, limited data are available on HLA-B27 and interleukin-17 inhibitors.
John D. Reveille, Martin Rudwaleit, Proton Rahman, Jose A. Maldonado-Cocco, Marina Magrey, Rebecca Bolce, Khai Jing Ng, Theresa Hunter Gibble, Jeffrey Lisse, So Young Park, Andris Kronbergs, Victoria Navarro-Compán   +11 more
doaj   +2 more sources

Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab

Therapeutics and Clinical Risk Management, 2017
Tessa L Hanley,1 Zenas ZN Yiu2,3 1Fairfield General Hospital, Bury, 2Centre for Dermatology, 3Centre for Pharmacoepidemiology and Drug Safety, Manchester Academic Health Science Centre, Manchester, UK Abstract: Developments in the understanding of the ...
Hanley TL, Yiu ZZN
exaly   +2 more sources

Real-world evidence for ixekizumab in the treatment of psoriasis and psoriatic arthritis: literature review 2016–2021

Journal of Dermatological Treatment, 2023
Objectives To describe the results of a structured literature review of real-world outcomes with ixekizumab in patients with psoriasis (PsO) and/or psoriatic arthritis (PsA).
Adam Reich, Catherine Reed, Christopher Schuster, Camille Robert, Tamas Treuer, Ennio Lubrano   +5 more
doaj   +1 more source

Pregnancy outcomes in patients with psoriasis, psoriatic arthritis, or axial spondyloarthritis receiving ixekizumab

Journal of Dermatological Treatment, 2022
Background Psoriasis, psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) are chronic inflammatory diseases that often affect women of childbearing age.
A. Egeberg, L. Iversen, A. B. Kimball, S. Kelly, E. Grace, H. Patel, W. Xu, G. Gallo, E. Riedl, S. R. Feldman   +9 more
doaj   +1 more source

Ixekizumab improves sleep and work productivity in patients with non-radiographic axial spondyloarthritis: results from the COAST-X trial at 52 weeks

BMC Rheumatology, 2021
Background Patients with non-radiographic axial spondyloarthritis experience negative impacts on sleep, work productivity, and activity impairment. Ixekizumab, a monoclonal antibody selectively targeting interleukin-17A, has shown efficacy in treating ...
Atul Deodhar, Philip Mease, Helena Marzo-Ortega, Theresa Hunter, David Sandoval, Andris Kronbergs, Steven Lauzon, Ann Leung, Victoria Navarro-Compán   +8 more
doaj   +1 more source

Ixekizumab Results in Persistent Clinical Improvement in Moderate-to-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical Trial

Acta Dermato-Venereologica, 2020
Ixekizumab was efficacious in treating moderate-to-severe genital psoriasis over 12 weeks. We evaluated the long-term efficacy and safety of ixekizumab for up to 52 weeks.
Lyn Guenther, Alison Potts Bleakman, Jamie Weisman, Yves Poulin, Lynda Spelman, Russel Burge, Janelle Erickson, Kristin Todd, Clinton C. Bertram, Caitriona Ryan   +9 more
doaj   +1 more source

Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1)

Rheumatology and Therapy, 2023
Introduction The efficacy and safety of ixekizumab, an anti-interleukin-17A antibody, in patients with severe symptoms of psoriatic arthritis are largely unexplored.
Hideto Kameda, Kohei Hagimori, Yoji Morisaki, Thorsten Holzkämper, Ayako Konomi, Hiroaki Dobashi   +5 more
doaj   +1 more source